SOST and hyperinsulinemic hypoglycemia, familial, 4: Thus, patients with OPPG resulting from loss of function in the LRP5 gene should be administered with an antagonist of SOST/sclerostin action, while the inhibitors of WNT signaling may hinder the overgrowth of bone in SOST deficiency-related sclerosing diseases [145].